Amplia Therapeutics Ltd. (INNMF)

[BC239]

Robert Peach is on the Innate board and sold Receptos, a company I believe he co-founded, for $7.2 billion a couple of years ago. As I understand it, Receptos had a drug in 2B trial for the first phase of MS and for ulcerative colitis.
Celgene, the buyer, spoke at a conference recently suggesting they expect that drug to sell in the $4-6 billion area.
It has been published that the market for the Innate drug is $7 billion and there is no other drug for SPMS. If, for example, the drug got a 50% market share plus there is use for the drug in the cancer arena as also published (ovarian cancer was mentioned in an article I read) we could be looking at sales at a similar size to the Receptos/Celgene drug, don't you think ?
Take $7.2 billion into around 250,000,000 shares and you have a very happy pay day. Who knows what will happen but I'd welcome other opinions.